Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when QURE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsuniQure receives FDA alignment on AMT-130 accelerated approval pathway, plans Q3 BLA
Filed July 29, 2026 · Period ending July 29, 2026 · ~1 min read
Key Changes
-
high
FDA confirmed in July 2026 that a BLA submission for AMT-130 under accelerated approval is reasonable based on existing clinical data; company plans Q3 2026 submission. FDA seeks alignment on confirmatory study design prior to BLA, including consideration of standard-of-care control instead of sham procedure.
Exhibit 99.1 view on EDGAR → -
high
Closed $259M follow-on offering in June 2026 at $45.50/share (5.7M shares). Cash position expected to reach $810.3M at June 30, 2026, expected to fund operations into 2030.
Exhibit 99.1 view on EDGAR → -
high
Q2 2026 net loss widened to $81.1M ($1.22/share) from $37.7M ($0.69/share) in Q2 2025, driven by $16.0M loss on pre-funded warrants and unfavorable FX movements. Revenue rose to $5.8M from $5.3M.
Exhibit 99.1 view on EDGAR → -
medium
AMT-260 epilepsy trial: three of six low-dose patients achieved 79%-100% reductions in disabling seizures at months 4-6; remaining three showed variable results (-33% to +36%). No serious adverse events or immunosuppression required.
Exhibit 99.1 view on EDGAR → -
medium
AMT-191 Fabry trial dosing remains paused in mid- and high-dose cohorts following asymptomatic liver enzyme elevations in two mid-dose patients (dose-limiting toxicities). Elevations resolved by end of May 2026 after immunosuppression.
Exhibit 99.1 view on EDGAR →
Summary
uniQure disclosed that the FDA confirmed in July 2026 that a BLA submission for AMT-130 under the accelerated approval pathway is reasonable based on existing clinical data, with the company planning to submit in Q3 2026. The FDA is seeking alignment on the confirmatory study design prior to submission, including consideration of a randomized standard-of-care control instead of a sham procedure, and expects the confirmatory study to be well underway or fully enrolled at the time of accelerated approval. This regulatory alignment represents a significant milestone for the company's lead Huntington's disease program.
The company raised $259 million gross proceeds through a June 2026 follow-on offering at $45.50 per share, bringing its cash position to $810.3 million as of June 30, 2026—sufficient to fund operations into 2030. The Q2 2026 net loss widened to $81.1 million from $37.7 million in the prior-year quarter, primarily due to a $16.0 million loss on pre-funded warrants and unfavorable foreign currency movements. Early-stage pipeline programs showed mixed results: AMT-260 for epilepsy demonstrated meaningful seizure reductions in half of the low-dose cohort, while AMT-191 for Fabry disease remains paused in higher-dose cohorts following resolved liver enzyme elevations in two patients.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
uniQure announced Q2 2026 financial results and corporate update via press release.
Added in current filing · verify on EDGAR →
On July 29, 2026, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and providing a corporate update.
The company disclosed its second quarter 2026 financial results through a press release. The 8-K body does not contain the actual financial figures—those appear in the attached Exhibit 99.1 press release, which is furnished rather than filed.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
In June 2026, the Company closed an upsized underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, including the full exercise of the underwriters’ option to purchase additional shares. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were $259 million.
uniQure raised $259 million gross proceeds through a June 2026 follow-on offering of 5,686,813 shares at $45.50 per share. Cash, cash equivalents, and current investment securities totaled $810.3 million as of June 30, 2026, up from $622.5 million at year-end 2025. The company expects these resources to fund operations into 2030.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 30, 2026 · How we verify